This interactive, case-based OncoBlast activity helps clinicians navigate treatment decisions in NSCLC using molecular testing, targeted therapies, and immunotherapy. Through ABIM-style questions and expert explanations, learners will explore optimal diagnostic and treatment approaches based on actionable biomarkers.
Course Accreditations
Course Summary
| Events Starts | Events Ends |
|---|---|
| 1/1/2025 | 12/31/2025 |
Faculty
Siddhartha Devarakonda (MD, Swedish Cancer Institute)
Dr. Sid Devarakonda trained and worked on faculty at the Washington University in St. Louis before joining Swedish Cancer Institute in Seattle as the Director of Thoracic Medical Oncology and Washington State University as an Associate Professor. His research is focused on understanding cancers utilizing sequencing technologies. He has been a part of consortia such as TCGA. He is particularly interested in understanding the molecular underpinnings of never-smoker lung cancer and mechanisms of treatment resistance in lung cancers.
Disclosure
Financial relationships Yes, I have had a financial relationship with an ineligible company within the past 24 months. Financial relationships: Attribution: Self Type of financial relationship: Other Ineligible company: AstraZeneca Attribution: Self Type of financial relationship: Other Ineligible company: Jazz Attribution: Self Type of financial relationship: Other Ineligible company: Genentech Attribution: Self Type of financial relationship: Other Ineligible company: Takeda Attribution: Self Type of financial relationship: Other Ineligible company: Eli Lilly Attribution: Self Type of financial relationship: Other Ineligible company: Daiichi-Sankyo Attribution: Self Type of financial relationship: Other Ineligible company: Apollomics
- Medical Oncologists
- Surgeons
- Radiation Oncologists
- Pathologists
- Oncology Fellows
- Oncology Nurses
- Nurse Practitioners
- Physician Assistants
- Pharmacists
Target Audience
- Apply biomarker testing to guide NSCLC treatment choices.
- Select appropriate targeted or immunotherapy based on clinical scenarios.
- Recognize and manage the toxicities of modern lung cancer treatments.
Learning Objectives
Upon successful completion of this educational activity, participants will be able to: